<DOC>
	<DOCNO>NCT00003541</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy , radiation therapy , peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase I/II trial study effectiveness combination chemotherapy , radiation therapy , peripheral stem cell transplantation treat patient stage III stage IV mantle cell lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy , Radiation Therapy , Peripheral Stem Cell Transplantation Treating Patients With Stage III Stage IV Mantle Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response 8 week induction chemotherapy program consist cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) patient mantle cell lymphoma . II . Evaluate efficacy ifosfamide , carboplatin , etoposide ( ICE ) chemotherapy filgrastim ( G-CSF ) peripheral blood stem cell ( PBSC ) mobilization patient population . III . Evaluate safety efficacy ICE follow total body irradiation high dose cyclophosphamide etoposide patient population . IV . Assess contamination PBSCs lymphoma cell follow mobilization chemotherapy G-CSF patient population . OUTLINE : Patients receive induction chemotherapy cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 , oral prednisone daily day 2-6 , filgrastim ( G-CSF ) subcutaneously daily day 6-10 . Treatment repeat every 14 day 4 course . Patients receive consolidation chemotherapy ifosfamide IV 24 hour carboplatin IV day 2 , etoposide IV daily day 1-3 , G-CSF subcutaneously day 5-12 course 1 , day 5 course 2 continue peripheral blood stem cell ( PBSC ) collection . Treatment repeat every 14 day 2 course . Following PBSC collection , patient receive total body irradiation twice day 4 day plus etoposide IV 72 hour day -6 , -5 , -4 cyclophosphamide IV daily day -3 -2 . PBSCs infuse day 0 . Patients receive G-CSF IV subcutaneously twice day begin day 1 . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 14-24 patient accrue study within two year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV mantle cell lymphoma ( diffuse , nodular , mantle zone , blastic variant ) PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : No chronic active persistent hepatitis Bilirubin le 2 mg/dL ( unless history Gilbert 's disease ) Renal : No history chronic renal insufficiency Creatinine le 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : At least 6 month since myocardial infarction No unstable angina No cardiac arrhythmias chronic atrial fibrillation LVEF least 50 % Pulmonary : DLCO least 50 % Other : No medical illness would preclude study treatment No uncontrolled infection No history malignancy , curatively treat basal cell skin cancer carcinoma situ cervix Not pregnant nursing Fertile patient must use effective contraception Not HIV positive PRIOR CONCURRENT THERAPY : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
</DOC>